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BSTRACT
 
Background
 
Cerebral malaria has a mortality rate 
of 10 to 30 percent despite treatment with parenteral 
quinine, a situation that may worsen with the spread 
of quinine resistance. Artemether is a new antima-
larial agent that clears parasites from the circulation 
more rapidly than quinine, but its effect on mortality 
is unclear.
 
Methods
 
We conducted a randomized, unblind-
ed comparison of intramuscular artemether and 
intramuscular quinine in 576 Gambian children 
with cerebral malaria. The primary end points of 
the study were mortality and residual neurologic 
sequelae.
 
Results
 
Fifty-nine of the 288 children treated with 
artemether died in the hospital (20.5 percent), as 
compared with 62 of the 288 treated with quinine 
(21.5 percent). Among the 418 children analyzed at 
approximately five months for neurologic disease, 
residual neurologic sequelae were detected in 7 of 
209 survivors treated with artemether (3.3 percent) 
and 11 of 209 survivors treated with quinine (5.3 per-
cent, P
 

 
0.5). After adjustment for potential con-
founders, the odds ratio for death was 0.84 (95 per-
cent confidence interval, 0.53 to 1.32) in the 
artemether group, and for residual neurologic se-
quelae, 0.51 (95 percent confidence interval, 0.17 to 
1.47). There were fewer local reactions at the injec-
tion site with artemether than with quinine (0.7 per-
cent vs. 5.9 percent, P
 

 
0.001).
 
Conclusions
 
Artemether is as effective as quinine 
in the treatment of cerebral malaria in children. 
(N Engl J Med 1996;335:69-75.)
 
©1996, Massachusetts Medical Society.
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BOUT half a million African children die
each year as a result of cerebral malaria.
The recommended therapy is parenteral
quinine, but the case fatality rate is 10 to
30 percent despite treatment.
 
1,2
 
 Quinine has several
other limitations. Because of its potential toxicity it
is ideally administered by carefully controlled intra-
venous infusion — a procedure that is often imprac-
tical in rural health clinics, especially in young chil-
dren. Under these circumstances, the World Health
Organization recommends administration by the
intramuscular route,
 
3
 
 which is equally effective in
terms of parasite clearance but tends to produce ir-
ritation and, infrequently, abscess formation at the
site of injection.
 
4
 
 Of increasing concern is the de-
clining efficacy of quinine in parts of Southeast
Asia,
 
5
 
 a trend that could prove disastrous if it spreads
to Africa, where most deaths from malaria occur.
Thus, there is an urgent need to identify new forms
of therapy for severe malaria that are economical and
practical alternatives to quinine and, ideally, improve
the clinical outcome of cerebral malaria.
Among potential alternatives to quinine, the arte-
misinin (qinghaosu) derivatives have attracted spe-
cial interest because of the rapidity with which they
reduce 
 
Plasmodium falciparum
 
 parasitemia.
 
6
 
 Arte-
mether, the methyl ether of dihydroartemisinin (the
A
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active metabolite of artemisinin), is formulated as an
intramuscular injection that has been shown in sev-
eral clinical studies to clear parasites more quickly
than quinine.
 
6
 
 In addition, a study in Malawi report-
ed that children with cerebral malaria recovered more
quickly from coma when treated with artemether
than when treated with quinine.
 
7
 
 These and other
promising findings have led to the widespread, but
so far unproved, belief that artemether may reduce
the rate of death from cerebral malaria. Thus, we
compared the ability of artemether and quinine to
prevent death or neurologic sequelae in children
with cerebral malaria.
 
METHODS
 
Study Population
 
The study was conducted in the Gambia, West Africa, between
1992 and 1994. Recruitment began at the Royal Victoria Hospi-
tal in Banjul, which is the chief referral hospital for the western
part of the country. In 1993, the study was extended to include
Sibanor Health Centre, a mission hospital 90 km from Banjul that
serves as a primary and secondary health care facility for a mainly
rural population. Unconscious children one to nine years of age
who were brought to Royal Victoria Hospital or Sibanor Health
Centre were eligible for the study if they had a Blantyre coma
score of 2 or less,
 
8
 
 asexual forms of 
 
P. falciparum
 
 were identified
on a thick blood film, and a parent or guardian gave informed
consent. To confine recruitment to patients with true cerebral
malaria, patients with diseases other than malaria at the time of
admission were excluded, as were those who recovered conscious-
ness immediately after the correction of hypoglycemia or within
one hour if they were convulsing on admission. Those treated
with quinine before admission were also excluded; no child had
previously received artemether.
 
Study Design
 
Intramuscular artemether and intramuscular quinine were com-
pared in an open, randomized trial that was part of a larger trial
of cerebral-malaria intervention, in which a monoclonal antibody
against tumor necrosis factor (TNF) was also evaluated. A two-
by-two factorial design was used to allow artemether to be com-
pared with quinine while anti-TNF therapy was compared with
placebo in the same group of patients. The statistical principles
of factorial design are well established.
 
9,10
 
 
The treatment code for each child was stored in a sealed enve-
lope that was opened after the admission procedure was complet-
ed and parental consent had been obtained. To ensure that disease
severity was well matched between the treatment groups, random-
ization was stratified according to the coma score at admission
(0, 1, or 2) and the study center and was balanced over time in
blocks of 10 for both antimalarial and anti-TNF therapy. The dif-
ferent dose schedules used for artemether and quinine meant that
the ward staff members were aware of the patients’ treatment as-
signments. However, the assessment of neurologic sequelae in sur-
vivors was carried out by a doctor who was unaware of the treat-
ment code. In addition to the randomization for artemether and
quinine, each child was also assigned to receive either anti-TNF
therapy (5 mg per kilogram of body weight) or placebo, given as
a double-blinded intravenous dose. The randomization procedure
ensured that anti-TNF therapy and placebo were evenly distribut-
ed between the quinine and artemether groups.
The primary end points of the study were death in the hospital
and residual neurologic sequelae that persisted when the child
was assessed during the dry season following the illness. The sec-
ondary end points were rates of clearance of parasites and fever,
length of time to recovery from coma, and neurologic sequelae
at discharge and one month after admission. The sample size was
determined at the outset, to provide an 80 percent probability of
detecting a 33 percent reduction in mortality at the 5 percent
significance level. These estimates were based on our previous ex-
perience of a 25 to 30 percent mortality rate in this group of pa-
tients and on data from Southeast Asia suggesting that arte-
mether might reduce mortality by up to 50 percent.
 
6
 
Antimalarial-Treatment Schedules
 
Patients assigned to the artemether group received intramuscu-
lar injections of artemether (Paluther, Rhône–Poulenc Rorer, Vit-
ry-sur-Seine, France) in the anterior thigh for four days, in an ini-
tial dose of 3.2 mg per kilogram, followed by daily doses of 1.6
mg per kilogram. Those assigned to the quinine group received
intramuscular injections of quinine dihydrochloride (Rotexmedi-
ca, Trittau, Germany) in the anterior thigh for five days, in an ini-
tial dose of 20 mg per kilogram, followed by a dose of 10 mg per
kilogram every 12 hours. Because of the irritant effect of intra-
muscular quinine, its concentration was diluted to 60 mg per mil-
liliter and the initial dose divided between thighs. Once a patient
was able to swallow, intramuscular injections were replaced by
oral quinine sulfate. With the above regimens, it was found in the
first year of the study that recrudescence of parasitemia was rel-
atively common in both treatment groups at one month of fol-
low-up. In the second and third years of the study, to reduce the
rate of recrudescence, pyrimethamine–sulfadoxine (Fansidar, Hoff-
mann–LaRoche, Reinach, Switzerland) was added to the antima-
larial treatment regimen in both groups, in a dose as close as pos-
sible to one of 1.25 mg of pyrimethamine per kilogram and 25
mg of sulfadoxine per kilogram orally. Pyrimethamine–sulfadox-
ine was given only after a child had fully regained consciousness
and after parasitemia and fever had cleared, to avoid affecting the
secondary end points of the study.
 
Clinical Assessment and Management
 
On admission, the patient’s history and clinical findings were re-
corded on standardized forms. A venous blood sample was ob-
tained for preparation of a thick blood film, estimation of the
blood glucose level (with Haemoglucotest 1-44 R strips and a Re-
flolux S meter, Boehringer Mannheim, Livingston, United King-
dom), for the determination of packed-cell volume, and for blood
culture, hematologic analysis, and biochemical analysis. Hypogly-
cemia, defined as a blood glucose level below 40 mg per deciliter
(2.2 mmol per liter), was treated immediately with 1 ml of 50 per-
cent glucose per kilogram intravenously. Convulsions were treated
initially with diazepam (0.5 mg per kilogram rectally or 0.3 mg
per kilogram intravenously), followed if necessary by paraldehyde
(0.1 ml per kilogram). Children with repeated or refractory con-
vulsions received phenobarbital (15 mg per kilogram intramuscu-
larly). Lumbar puncture was performed, unless clinically contrain-
dicated, to rule out meningitis. Fluids (4 percent glucose in 0.18
percent saline solution) were given intravenously to comatose pa-
tients. The packed-cell volume was measured daily, and a blood
transfusion (15 ml per kilogram) was given if it fell below 15 per-
cent. Cases of secondary infection (primarily aspiration pneu-
monia) were treated with chloramphenicol. Vital signs (including
temperature, pulse, respiratory rate, and coma score) were record-
ed every 4 hours for the first 24 hours and then every 6 hours until
discharge. Blood glucose measurements were repeated after 4 and
12 hours and when clinically indicated. At the Royal Victoria Hos-
pital, blood films were examined every 12 hours and the number
of asexual parasites per 200 white cells (thick film) or 1000 red
cells (thin film) was counted in order to determine the level of par-
asitemia. Each blood film was examined by two independent ob-
servers who were unaware of the treatment code. Data on admis-
sion characteristics, primary end points of the study, and time to
recovery from coma were recorded at both study centers. Sequen-
tial observations on the clearance of parasites and resolution of fe-
ver were made only at Royal Victoria Hospital.
Each child underwent a physical examination with neurologic
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assessment at the time of discharge. A child was considered to
have neurologic sequelae if he or she had any of the following neu-
rologic abnormalities: paresis, ataxia, spasticity, floppiness, hearing
defects, visual-field defects, aphasia, behavioral abnormalities, or
developmental regression. All surviving children were asked to re-
turn one month after admission, for a further detailed neurologic
assessment by a clinical investigator. This included a questionnaire
on the child’s behavior and performance and a detailed examina-
tion. Those who had neurologic sequelae at one month were re-
viewed by the same clinical investigator during the following dry
season, approximately five months after admission. Those without
evident sequelae at one month were visited by a field worker, and
if there was any doubt about their health or performance, they
were referred to the clinical investigator for further evaluation.
Ninety-five percent of the survivors were reexamined one month
after admission, and 92 percent approximately five months after
admission. In both treatment groups a similar proportion of pa-
tients was lost to follow-up, most often because of emigration
from the Gambia or an incorrect address.
 
Statistical Analysis
 
The protocol specified two initial procedures to be completed
before a full analysis of the data was undertaken. First, because of
the factorial design, it was necessary to examine whether random-
ization to the group receiving anti-TNF therapy or placebo might
have affected any difference in results between artemether and
quinine. Second, we used a multiple logistic-regression model,
omitting treatment as a variable, to identify admission variables
that were related to clinical outcome and that were potential con-
founders. In the case of death, these were temperature, pulse rate,
the presence of hypoglycemia at admission, coma score, and study
center; in the case of neurologic sequelae, they were duration of
coma, coma score, and the presence of hypoglycemia at admis-
sion. In analyzing the effect of antimalarial treatment, and specif-
ically when determining odds ratios, we used a multiple logistic-
regression model to correct for these potential confounders, as
well as for any possible effect of anti-TNF therapy on the primary
outcome measures.
Discrete data were analyzed by the chi-square test or Fisher’s
exact test, with stratified analysis by the Mantel–Haenszel test and
multivariate analysis by unconditional logistic regression. Contin-
uous secondary end points that were normally distributed were
analyzed by Student’s t-test, after the application of Bartlett’s test
for homogeneity of variance; those that were not normally dis-
tributed were analyzed by the Wilcoxon test. Survival was com-
pared with use of Kaplan–Meier plots and the log-rank test, with
multivariate analysis by Cox regression. Different multivariate mod-
els were compared with the likelihood-ratio test.
The study was approved by the Gambian Government–Medical
Research Council Laboratories Ethics Committee. The study was
monitored by the Tropical Disease Research Program of the
World Health Organization, and the major outcome measures
were reviewed annually by an independent monitoring commit-
tee. A coded data base and detailed analytic plan were submitted
to the monitoring committee before the blinded randomization
codes were broken at the end of the study. The results presented
follow that analytic plan.
 
RESULTS
 
Clinical Features on Admission
 
A total of 576 children were randomly assigned to
receive artemether or quinine, 341 at Royal Victoria
Hospital and 235 at Sibanor Health Centre. Three
children who died after randomization but before
treatment could be given were excluded. The clinical
features on admission were similar in the two groups
(Table 1). Over half of the children had a history of
recent chloroquine treatment, and 39 percent had a
clinically notable plasma level of chloroquine (
 

 
100
ng per milliliter), but these features were unrelated to
outcome. On admission, 24 percent had hypoglyce-
mia and 8 percent had severe anemia (packed-cell vol-
ume 
 

 
15 percent, or hemoglobin 
 

 
5 g per deciliter).
 
Primary End Points
 
Mortality
 
Fifty-nine of the 288 children treated with arte-
mether died in the hospital (20.5 percent), as com-
pared with 62 of the 288 children treated with qui-
nine (21.5 percent, P
 

 
0.8) (Table 2). The adjusted
odds ratio for death among the children in the arte-
mether group was 0.84 (95 percent confidence in-
terval, 0.53 to 1.32). An intention-to-treat analysis,
which included the three children who died before
treatment was given, did not alter the odds ratio. As
shown in Figure 1, the length of time to death was
similar in the artemether group (median, 11 hours;
interquartile range, 5 to 25) and the quinine group
(median, 13 hours; interquartile range, 5 to 26;
P
 

 
0.8 by the log-rank test). One child in the qui-
nine group, who was well at the time of discharge,
died at home four days later.
 
Sequelae
 
Neurologic assessment was carried out during the
dry season in 418 of the 454 survivors (92 percent),
 
*Plus–minus values are means 
 

 
SD.
†Hypoglycemia was defined as a blood glucose level below
40 mg per deciliter (2.2 mmol per liter).
‡Severe anemia was defined as a packed-cell volume below
15 percent or a hemoglobin concentration below 5 g per
deciliter.
 
T
 
ABLE
 
 1.
 
 B
 
ASE
 
-L
 
INE
 
 C
 
HARACTERISTICS
 
 
 
OF
 
 
 
THE
 
P
 
ATIENTS
 
 A
 
CCORDING
 
 
 
TO
 
 T
 
REATMENT
 
 A
 
SSIGNMENT
 
.*
 
C
 
HARACTERISTIC
 
A
 
RTEMETHER
 
(N
 

 
288)
Q
 
UININE
 
(N
 

 
288)
 
Female sex (%) 47.2 50.5
Age (mo) 48.0
 

 
21.6 46.0
 

 
21.4
Duration of coma (hr)
Median
Range
6.0
1–150
6.0
1–96
Prior chloroquine treatment (%) 55.8 59.3
Temperature (°C) 38.8
 

 
1.1 38.8
 

 
1.0
Pulse rate (per minute) 147
 

 
23.0 145
 

 
22.5
Respiration rate (per minute) 51
 

 
15.1 50
 

 
13.5
Coma score (%)
0
1
2
22.2
31.6
46.2
20.5
31.9
47.6
Hypoglycemia (%)† 26.3 22.3
Degree of parasitemia (geometric 
mean count/mm
 
3
 
)
57,106 55,471
Hemoglobin (g/dl) 8.1
 

 
2.6 8.4
 

 
2.5
Severe anemia (%)‡ 8.7 8.1
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an average of five months (range, three to nine) after
admission. Residual neurologic sequelae were detect-
ed in 7 of 209 survivors who had received artemether
(3.3 percent), as compared with 11 of 209 of those
treated with quinine (5.3 percent). This difference
was not statistically significant (P
 

 
0.5). The adjust-
ed odds ratio for residual sequelae for children in the
artemether group was 0.51 (95 percent confidence
interval, 0.17 to 1.47).
Because of the factorial design, we examined
whether the differences between artemether and
quinine were the same for children treated with anti-
TNF as for those who received placebo. Among chil-
dren treated with artemether, there were 24 deaths
in the anti-TNF group (n
 

 
138), 30 in the placebo
group (n
 

 
145), and 5 in the group excluded from
anti-TNF analysis (n
 

 
5). Among those who re-
ceived quinine, there were 32 deaths in the anti-TNF
group (n
 

 
142), 28 in the placebo group (n
 

 
140),
and 2 in the group excluded from anti-TNF analysis
(n
 

 
6). With respect to residual neurologic sequelae
among survivors treated with artemether, there were
5 cases in the anti-TNF group (n
 

 
105) and 2 in the
placebo group (n
 

 
104). Among survivors who re-
ceived quinine, there were 8 cases of residual se-
quelae in the anti-TNF group (n
 

 
100), 3 in the
placebo group (n
 

 
105), and none in the group ex-
cluded from anti-TNF analysis (n
 
4). These data
provide no evidence of an interaction between arte-
mether and anti-TNF (chi-square value for the anal-
ysis of mortality, 0.75; P0.4; chi-square value for
the analysis of neurologic sequelae, 0.018; P0.9).
Furthermore, removing anti-TNF therapy from the
list of potential confounding variables caused little
change in the adjusted odds ratios for mortality
(odds ratio, 0.85; 95 percent confidence interval,
0.53 to 1.32) and neurologic sequelae (odds ratio,
0.49; 95 percent confidence interval, 0.17 to 1.43).
Secondary End Points
Sequelae at Discharge and One Month
At the time of discharge, 21.0 percent of survivors
in the artemether group and 25.2 percent in the qui-
nine group had neurologic sequelae. At one month
the proportions were 8.3 percent and 9.8 percent,
respectively. Neither of these differences was statisti-
cally significant.
Recovery from Coma
Eleven of the 455 children who were discharged
from the hospital did not fully regain consciousness;
6 had received artemether and 5 had received qui-
nine. Among the 444 children who did recover from
coma, the median recovery time was 26 hours
among those treated with artemether and 20 hours
among those treated with quinine (P0.046 by the
Wilcoxon test) (Table 3). The probability of re-
covering from coma in the artemether and quinine
groups, respectively, was 0.48 and 0.59 within 24
hours, 0.77 and 0.80 within 48 hours, and 0.91 and
0.88 within 72 hours.
Clearance of Parasites
The times needed for the parasite counts to fall by
50 percent and 90 percent of the admission value
and to clear completely were significantly shorter in
*CI denotes confidence interval.
†In the analysis of mortality the values were adjusted for temperature, pulse rate, presence of hypoglycemia, coma score,
study center, and anti-TNF–therapy status. In the analysis of neurologic sequelae values were adjusted for the duration
of coma before admission, presence of hypoglycemia, coma score, and anti-TNF–therapy status.
‡Data on one child in the quinine group, who died at home four days after discharge, were excluded.
§One month after admission, 95.2 percent of surviving children returned for neurologic assessment (433 of 455); ap-
proximately five months later, during the dry season, 92.1 percent (418 of 454) returned for assessment of any residual
sequelae.
TABLE 2. MORTALITY AND INCIDENCE OF NEUROLOGIC SEQUELAE AMONG CHILDREN TREATED 
FOR CEREBRAL MALARIA WITH ARTEMETHER OR QUININE.*
VARIABLE ARTEMETHER QUININE CRUDE ANALYSIS ADJUSTED ANALYSIS†
ODDS RATIO
(95% CI)
P
VALUE
ODDS RATIO
(95% CI)
P
VALUE
no./total no. (%)
Primary end point
Death in the hospital‡
Residual neurologic se-
quelae§
59/288 (20.5)
7/209 (3.3)
62/288 (21.5)
11/209 (5.3)
0.94 (0.62–1.43)
0.62 (0.21–1.78)
0.8
0.5
0.84 (0.53–1.32)
0.51 (0.17–1.47)
0.5
0.2
Secondary end point
Neurologic sequelae at dis-
charge
Neurologic sequelae at
1 month§
48/229 (21.0)
18/218 (8.3)
57/226 (25.2)
21/214 (9.8)
0.79 (0.50–1.25)
0.83 (0.41–1.68)
0.3
0.7
0.81 (0.50–1.31)
0.78 (0.39–1.58)
0.4
0.5
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children treated with artemether than in those treat-
ed with quinine (P0.01 for each comparison by
the Wilcoxon test) (Table 3 and Fig. 2). In the first
year of the study, 29.6 percent of the artemether-
treated patients and 17.6 percent of the quinine-
treated patients had parasitemia after one month of
follow-up (P0.4). In subsequent years, when pyr-
imethamine–sulfadoxine was given before discharge,
the rates dropped to 10.6 percent for the artemether
group and 9.4 percent for the quinine group.
Clearance of Fever
The time to clearance of fever, defined as the time
needed for the rectal temperature to fall below
38.0°C for at least 24 hours, was 30 hours in the ar-
temether group and 33 hours in the quinine group
(P0.8 by the Wilcoxon test) (Table 3 and Fig. 3).
Complications of Cerebral Malaria
Significantly more children in the artemether
group than in the quinine group had convulsions af-
ter treatment began (38.5 percent vs. 28.1 percent,
P0.01). After adjustment for convulsions before
the start of treatment and the duration of coma, the
odds ratio was 1.86 (95 percent confidence interval,
1.28 to 2.71; P0.001 by multiple logistic-regres-
sion analysis). Though not statistically significant,
there was a greater tendency for hypoglycemia to
occur after treatment with quinine than after arte-
mether treatment (14.6 percent vs. 10.1 percent;
P0.13). After stratification according to the pres-
ence of hypoglycemia on admission, the odds ratio
was 1.69 (95 percent confidence interval, 0.97 to
2.98; P0.07 by the Mantel–Haenszel chi-square
test). The two groups were similar in terms of other
complications, including the extent of the fall in he-
moglobin levels over a period of seven days, the need
for blood transfusions, and the incidence of second-
ary bacterial infections (data not shown).
Side Effects
Local reactions at the site of the intramuscular
injections were more common in the quinine-treat-
ed children than in the artemether-treated patients
(5.9 percent vs. 0.7 percent, P0.001). An abscess
requiring incision and drainage developed in six chil-
dren (five in the quinine group and one in the arte-
mether group). One case of urticarial rash was ob-
served in the quinine group.
DISCUSSION
Our results show that, in terms of preventing death
or neurologic sequelae caused by cerebral malaria, ar-
temether is about as effective as intramuscular qui-
nine, the treatment currently recommended by the
World Health Organization for tropical clinics with
limited resources.3 Artemether is a practical alterna-
tive to quinine, since it is less irritating when given
intramuscularly and need be given only once a day.
Although parasites were cleared from the circu-
lation significantly faster by artemether than by qui-
nine (median time to decrease in the levels to 50 per-
cent of the admission value, 9 hours vs. 14 hours;
P0.005), the fatality rate was similar for both drugs
(20.5 percent vs. 21.5 percent). It had been widely
anticipated that a more rapid reduction of parasitemia
would bring about a corresponding reduction in mor-
tality. Several smaller trials in Southeast Asian adults
with various forms of severe malaria suggested that
treatment with artemisinin derivatives might halve
mortality.6 In the context of childhood cerebral ma-
laria in Africa, we found no significant difference in
Figure 1. Kaplan–Meier Analysis of Survival of 576 Children
Treated for Cerebral Malaria with Artemether or Quinine.
Seventy-three percent of all deaths occurred within 24 hours
after admission, and 91 percent within 48 hours. The hazard ra-
tio for artemether was 0.99 (95 percent confidence interval,
0.84 to 1.17).
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TABLE 3. LENGTH OF TIME TO CLEARANCE OF PARASITES, 
RESOLUTION OF FEVER, AND RECOVERY FROM COMA.
VARIABLE ARTEMETHER QUININE P VALUE
median (interquartile range)
Time to parasite clearance (hr)
Decrease to 50% of admission
value
Decrease to 10% of admission
value
Total clearance
9 (7–16)
22 (16–28)
48 (36–60)
14 (7–21)
25 (20–34)
60 (48–72)
0.005
0.008
0.001
Time to resolution of fever (hr)
Decrease in rectal temperature to 
38°C
Maintenance of rectal temperature 
38°C for at least 24 hr
8 (4–16)
30 (16–48)
12 (4–12)
33 (12–60)
0.8
0.8
Time to recovery from coma (hr) 26 (15–48) 20 (12–43) 0.046
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clinical outcome between patients given artemether
and those given quinine, although the adjusted odds
ratios had wide confidence limits and we cannot ex-
clude the possibility that artemether would reduce
mortality and sequelae if its use were widespread. Our
study was carried out in a region where P. falciparum
remains fully sensitive to quinine, and it is conceivable
that the benefit of artemether would be greater in re-
gions where quinine resistance occurs.
There has been concern that artemether may be
neurotoxic at high doses. This has been observed in
studies in animals given a dose of 15 mg per kilo-
gram daily for 28 days, though it has yet to be dem-
onstrated in humans.11 Our finding of an increased
incidence of convulsions in the artemether group,
together with a tendency toward a longer time to re-
covery from coma, could conceivably be due to such
an effect. But the data provide no evidence to sug-
gest that long-term neurologic damage is caused by
artemether at this dosage, since the incidence of
neurologic sequelae tended to be lower after treat-
ment with artemether than after treatment with qui-
nine. The proportion of survivors with evident neu-
rologic abnormalities at discharge was 21.0 percent
in children treated with artemether and 25.2 percent
in those who received quinine. It is encouraging to
note that this rate fell considerably over the follow-
ing three to nine months, to 3.3 percent and 5.3
percent, respectively.
A practical advantage of artemether is that it is
considerably less likely than quinine to cause reac-
tions at the site of intramuscular injection. In this
study, such reactions occurred in 5.9 percent of chil-
dren treated with intramuscular quinine despite the
fact that we used a diluted formula of quinine (60
mg per milliliter). In most cases the problem was
tenderness and induration at the injection site,
which resolved within a few weeks, but in some chil-
dren a sterile abscess developed that required inci-
sion and drainage. We also noted a tendency for
hypoglycemic episodes to occur more often after
treatment with quinine. Quinine is a potent stimu-
lator of insulin secretion and a well-known cause of
hypoglycemia in adults with falciparum malaria.12
Previous studies in African children were unable to
show a relation between quinine treatment and hy-
poglycemia, although 30 percent of Malawian chil-
dren had mildly elevated insulin levels during a hy-
poglycemic episode.13,14 Our findings suggest that
quinine contributes to hypoglycemia in a proportion
of children with cerebral malaria.
A disadvantage of both artemether and quinine is
that they are relatively inefficient at eradicating in-
fection.15,16 In the first year of the study it became
apparent that a large number of children who were
apparently free of parasitemia at discharge had para-
sites in their blood at the one-month follow-up (30
percent of the artemether group and 18 percent of
the quinine group). In the second and third years of
the study, all children were given pyrimethamine–
sulfadoxine at the end of the treatment period. To
avoid affecting the study end points, this was done
after the child had recovered from coma, fever, and
apparent parasitemia. As a result, the proportion of
survivors who had parasitemia at 28 days fell to ap-
proximately 10 percent in both the artemether and
quinine groups. The latter figure may represent the
underlying risk of acquiring a second infection.
A fundamental question arising from these data is
Figure 2. Mean (SE) Level of Parasitemia in Children Treated
for Cerebral Malaria with Artemether or Quinine.
The mean level of parasitemia was expressed as a percentage
of the admission value.
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Figure 3. Time to Resolution of Fever in Children Treated for
Cerebral Malaria with Artemether or Quinine.
The mean (SE) rectal temperature is shown for all patients
except those in whom a secondary infection was diagnosed.
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the extent to which antimalarial treatment can be
expected to reverse the pathologic process of cere-
bral malaria. Our finding of similar fatality rates in
the artemether and quinine groups suggests that the
speed of parasite clearance may be a relatively unim-
portant determinant of survival. In this case, part of
the explanation may be that artemether preferential-
ly accelerates the clearance of younger parasites,
which are those seen in the circulation, over more
mature parasites, which are located deep in the vas-
culature and mediate organ damage.17 
Our study shows that artemether is a well-toler-
ated and effective alternative to quinine and high-
lights the potential importance of the artemisinin
derivatives in the event that quinine resistance be-
comes common throughout the world. Whether ar-
temether should now be introduced as a first-line
treatment for cerebral malaria in Africa is a strategic
question of considerable importance. The World
Health Organization currently recommends that ar-
temether not be used as a first-line treatment in Af-
rica, in order to delay the development of resistance
to this valuable class of antimalarial compounds.18
Once the results of clinical trials in other parts of Af-
rica are known, this issue will need to be compre-
hensively reassessed.
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